SymbioCellTech, LLC (SCT), a late preclinical stage regenerative medicine company based in Salt Lake City, Utah, was established by clinical academic investigators at the University of Utah and University of Hamburg and is currently preparing IND-enabling studies in preparation for an IND submission to advance its novel Neo-Islets‚Ñ¢ technology into clinical proof-of-concept trials in patients with Type 1 Diabetes.
Neo-Islets‚Ñ¢ have been shown to be safe and efficacious in multiple preclinical animal models including an Investigational New Animal Drug (INAD) study of eight dogs where a safety profile has been clearly established over three years and strong efficacy has been demonstrated.
Neo-Islets‚Ñ¢ are under development to reduce, and potential eliminate the daily insulin injection needs, and the associated complications, for T1D patients.
Business Advisor
Chief Operating Officer
Chief Scientific Officer
Co-Founder and CEO
Co-Founder and VP
Strategic Advisor
Stay connected to everything happening at Altitude Lab.
You can trust us with your email. We don't spam.